专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

WO1993021893A1 COATING METHOD 审中-公开
标题翻译：涂料方法
公开(公告)号：WO1993021893A1
公开(公告)日：1993-11-11
申请号：PCT/JP1993000543
申请日：1993-04-27
申请人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , NISHII, Hiroyuki , KOBAYASHI, Masaru , TOYA, Kazutoshi , UCHIYAMA, Nobuo
发明人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
IPC分类号： A61J03/06
CPC分类号： A61K9/5089 , A61J3/005 , A61K9/5078 , B01J2/003 , B01J2/16
摘要： A coating method characterized in that, when the surfaces of solid particles kept flowing are spray-coated with thermally melted wax, a two-fluid nozzle adapted to mix thermally melted wax with a heating gas in and eject the resultant mixture from one flow passage and eject the heating gas from the other is used, the two-fluid nozzle having spray ports the diameter of which is in the range of 1.5 - 5.8 mm, the two-fluid nozzle having no needle valves. According to this method, the use of an organic solvent for melting wax is omitted, and complicated operations for pulverizing wax and thermally melting wax powder after it has been deposited on solid particles are not required. This method also prevents the clogging of the nozzle, the powdering of melted wax and the forming of agglomerated particles of wax, and permits simple and easy production of sustained release medicine and medicine for masking materials of unpleasant and bitter tastes.
摘要翻译：一种涂布方法，其特征在于，当保持流动的固体颗粒的表面用热熔融的蜡喷涂时，适用于将热熔融蜡与加热气体混合并将所得混合物从一个流动通道喷射出来的双流体喷嘴和喷出来自另一个的加热气体，双流体喷嘴的喷嘴的直径在1.5-5.8mm的范围内，双流体喷嘴没有针阀。根据该方法，省略了使用有机溶剂来熔融蜡，并且不需要在固体颗粒上沉积蜡之后粉碎蜡和热熔蜡蜡的复杂操作。该方法还可以防止喷嘴的堵塞，熔融蜡的粉化和聚集的蜡的形成，并且允许简单且容易地生产用于掩蔽不愉快和苦味的材料的缓释药物和药物。

32. 发明申请

WO1993012140A1 PEPTIDE WITH CELL ADHESION ACTIVITY AND POLYMERIC MODIFICATION THEREOF 审中-公开
标题翻译：具有细胞粘附活性和聚合物改性的肽
公开(公告)号：WO1993012140A1
公开(公告)日：1993-06-24
申请号：PCT/JP1992001594
申请日：1992-12-07
申请人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , AZUMA, Ichiro , SAIKI, Ikuo , KUSUNOSE, Naoto , IKEDA, Yoshiharu , ONO, Keiichi
发明人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
IPC分类号： C07K07/10
CPC分类号： C07K14/001 , A61K38/00 , C07K14/78 , Y02P20/55
摘要： A highly pure peptide with cell adhesion activity, comprising the repeating units of a cell adhesion core sequence and represented by the general formula (I): H-(Arg-Gly-Asp-Thr)n-OH, wherein n is an integer from 5 to 20; a polymer-modified peptide prepared by modifying the N-terminal amino group of the above peptide with a polyethylne glycol derivative; and a pharmaceutically acceptable salt thereof. Both peptides have potent pharmacological activities such as the inhibition of cancer metastasis and that of platelet agglutination, so that they are useful as cancer metastasis inhibitor, platelet agglutination inhibitor, remedy for wounds, and bone resorption inhibitor.
摘要翻译：一种具有细胞粘附活性的高纯度肽，其包含细胞粘附核心序列的重复单元并由通式（I）表示：H-（Arg-Gly-Asp-Thr）n-OH，其中n是 5至20; 通过用聚乙二醇衍生物修饰上述肽的N-末端氨基制备的聚合物改性肽; 及其药学上可接受的盐。两种肽都具有有效的药理活性，如抑制癌转移和血小板聚集，因此可用作癌转移抑制剂，血小板凝集抑制剂，伤口补救剂和骨吸收抑制剂。

33. 发明申请

WO1992020400A1 INSTRUMENT FOR APPLYING PHARMACEUTICAL TO INSIDE OF BRAIN 审中-公开
标题翻译：用于将药物应用于脑内的仪器
公开(公告)号：WO1992020400A1
公开(公告)日：1992-11-26
申请号：PCT/JP1992000658
申请日：1992-05-22
申请人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , KOKEN CO., LTD. , HAYAKAWA, Toru , YOSHIMINE, Toshiki , YAMAMOTO, Hiromu , SATO, Akira , IRIE, Tsunemasa , FUJIOKA, Keiji , TAKADA, Yoshihiro , SASAKI, Yoshio
发明人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , KOKEN CO., LTD.
IPC分类号： A61M37/00
CPC分类号： A61M37/00 , A61M39/0208 , A61M2210/0693
摘要： An instrument for applying a pharmaceutical to the inner part of brain, which is composed of pharmaceutical applying means (1) to hold pharmaceutical (2) therein and a plunger (4) detachably attached to said applying means so as to push pharmaceutical in said means toward one end of said means (1) wherein said applying means is fitted into a pharmaceutical introducing guide (5) buried in the patient's brain beforehand for introducing pharmaceutical into a guide hole (26) of said guide so that said pharmaceutical may be guided to the inner part of brain requiring treatment by the plunger (4) through a flexible guide tube (23) communicating with the guide hole of the introducing guide. Such an instrument may be composed of a tubular pharmaceutical indwelling member (30) to internally reserve pharmaceutical and a pharmaceutical indwelling member holder (32) to integrally hold said indwelling member together with a pushing rod (31) inserted thereinto. In this case, the applying instrument itself is inserted into the introducing guide (5) and indwelt therein.

34. 发明申请

WO1998023615A1 NOVEL NAPHTHYRIDINE DERIVATIVES 审中-公开
标题翻译：新型萘啶衍生物
公开(公告)号：WO1998023615A1
公开(公告)日：1998-06-04
申请号：PCT/JP1997004276
申请日：1997-11-25
申请人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
发明人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , MURAOKA, Masami , IORIYA, Katsuhisa , OHASHI, Naohito , YAGI, Hideki
IPC分类号： C07D471/04
CPC分类号： C07D471/04
摘要： Naphthyridine derivatives of general formula (I) and acid addition salts thereof, which exhibit an inhibitory activity against acyl-CoA cholesterol acyltransferase and therefor are useful as preventive and therapeutic agents for hyperlipemia, arteriosclerosis and diseases relate thereto: wherein A is an optionally substituted pyridine ring; X is -N(R )-CO- (wherein R is hydrogen, alkyl, substituted alkyl or the like); Z is a free bond, -NH-, C1 or C2 alkylene or -CH=CH-; Y is aryl or substituted aryl; and L is alkyl, substituted alkyl, aryl, substituted aryl or the like.
摘要翻译：对酰基-CoA胆固醇酰基转移酶具有抑制活性的通式（I）的萘啶衍生物及其酸加成盐可用作高脂血症，动脉硬化及其相关疾病的预防和治疗剂：其中A为任选取代的吡啶环; X是-N（R 2）-CO-（其中R 2是氢，烷基，取代的烷基等）; Z是游离键，-NH-，C 1或C 2亚烷基或-CH = CH-; Y为芳基或取代芳基; 并且L是烷基，取代的烷基，芳基，取代的芳基等。

35. 发明申请

WO1997045135A1 STABLE PHARMACEUTICAL COMPOSITION OF BDNF 审中-公开
标题翻译： BDNF稳定的药物组合物
公开(公告)号：WO1997045135A1
公开(公告)日：1997-12-04
申请号：PCT/JP1997001746
申请日：1997-05-26
申请人： REGENERON PHARMACEUTICALS, INC. , SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , TANAKA, Katsumi , KUMANO, Masashi
发明人： REGENERON PHARMACEUTICALS, INC. , SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
IPC分类号： A61K38/18
CPC分类号： A61K38/185 , A61K9/0019 , A61K9/19 , A61K47/26
摘要： A stable pharmaceutical composition of brain derived neurotrophic factor (BDNF) in the form of an aqueous solution or lyophilized one being suitable for a long-term storage, which contains a surfactant, especially nonionic surfactant (e.g., Tween 80) of 0.001 to 10 %, whereby the polymerization and the denaturation of BDNF are inhibited, and the biological activities of BDNF are maintained for a long time. Said lyophilized composition can be made more stable by addition of a sugar alcohol (e.g., mannitol) and/or an amino acid (e.g., glycine).
摘要翻译：水溶液形式的稳定的脑源性神经营养因子（BDNF）药物组合物或冻干的药物组合物适用于长期储存，其含有0.001至10％的表面活性剂，特别是非离子表面活性剂（例如吐温80）由此BDNF的聚合和变性被抑制，BDNF的生物活性长时间保持。所述冻干组合物可以通过加入糖醇（例如甘露糖醇）和/或氨基酸（例如甘氨酸）而变得更稳定。

36. 发明申请

WO1997020929A1 FIBROBLAST GROWTH FACTOR FGF-10 审中-公开
标题翻译： FIBROBLAST生长因子FGF-10
公开(公告)号：WO1997020929A1
公开(公告)日：1997-06-12
申请号：PCT/JP1996003579
申请日：1996-12-06
申请人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , ITOH, Nobuyukia , NEGORO, Takaharu , KATSUMATA, Takashi , TAGASHIRA, Shuzo
发明人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
IPC分类号： C12N15/12
CPC分类号： C07K14/50 , A61K38/00
摘要： A recombinant FGF-10 obtained by introducing an expression vector into which a DNA encoding a specific amino acid sequence has been integrated into a host cell, incubating the transformant thus obtained, and allowing it to produce the aimed protein. This recombinant FGF-10 is applicable to drugs and reagents utilizing the cell growth-promoting effect thereof.
摘要翻译：通过导入表达载体获得的重组FGF-10，其中将编码特定氨基酸序列的DNA整合到宿主细胞中，孵育由此获得的转化体，并使其产生目标蛋白。该重组FGF-10适用于利用细胞生长促进作用的药物和试剂。

37. 发明申请

WO1997012631A1 DRUG FOR AMELIORATING RENAL FUNCTION 审中-公开
标题翻译：用于改善肾功能的药物
公开(公告)号：WO1997012631A1
公开(公告)日：1997-04-10
申请号：PCT/JP1996001225
申请日：1996-05-09
申请人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , SANAKA, Tsutomu
发明人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
IPC分类号： A61K38/27
CPC分类号： A61K38/27 , Y10S930/12
摘要： A medicinal preparation which contains human growth hormones capable of recovering the renal function when administered to a patient who has renal insufficiency but does not undergo kidney dialysis. By administering this medicinal preparation, the loss of renal function represented by an extreme decrease in creatinine clearance or the reciprocal of blood creatinine level can be prevented and thus it can dispense with the dialytic treatment for patients with renal insufficiency.
摘要翻译：当给予具有肾功能不全但不经历肾透析的患者时，含有能够恢复肾功能的人生长激素的药物制剂。通过施用这种药物制剂，可以防止由肌酐清除率的极度降低或血肌酐水平的倒数所代表的肾功能的丧失，因此可以省去肾功能不全患者的透析治疗。

38. 发明申请

WO1996031488A1 NOVEL PYRIMIDINE DERIVATIVES EFFICACIOUS AS PSYCHOTROPIC DRUG AND PROCESS FOR THE PRODUCTION THEREOF 审中-公开
标题翻译：新型吡咯烷酮衍生物作为心血管药物有效，其生产方法
公开(公告)号：WO1996031488A1
公开(公告)日：1996-10-10
申请号：PCT/JP1996000895
申请日：1996-04-02
申请人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , IGARASHI, Jun-etsu , NISHIMURA, Tamiki , SUNAGAWA, Makoto
发明人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
IPC分类号： C07D239/47
CPC分类号： C07D239/47 , C07D239/38 , C07D239/48 , C07D401/12
摘要： Compound represented by general formula (I) or pharmacologically acceptable salts thereof: wherein A represents halogeno, optionally substituted lower alkyl or optionally substituted cycloalkyl; B and B are the same or different and each represents hydrogen or optionally substituted amino; X represents sulfur or oxygen; and Y , Y , Y , Y and Y are the same or different and each represents hydrogen, halogeno, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted aryl or optionally substituted heterocycle. The compounds have a potent interaction with central nervous system receptors such as dopamine or serotonin and are excellent in absorbability in vivo, stability, etc. Thus they are highly useful as a psychotropic drug with relieved side effects.
摘要翻译：由通式（I）表示的化合物或其药理学上可接受的盐：其中A 1表示卤代，任选取代的低级烷基或任选取代的环烷基; B 1和B 2相同或不同，各自表示氢或任选取代的氨基; X表示硫或氧; Y 1，Y 2，Y 3，Y 4和Y 5相同或不同，各自代表氢，卤代，任选取代的低级烷基，任选取代的环烷基，任选取代的低级烯基，任选取代的低级炔基，任选取代的芳基或任选取代的杂环。这些化合物与中枢神经系统受体如多巴胺或5-羟色胺具有强烈的相互作用，并且在体内的吸收性，稳定性等方面优异。因此，它们作为具有减轻副作用的精神药物是非常有用的。

39. 发明申请

WO1996014297A1 NOVEL LACTAM DERIVATIVES 审中-公开
标题翻译：新型乳糖衍生物
公开(公告)号：WO1996014297A1
公开(公告)日：1996-05-17
申请号：PCT/JP1995002256
申请日：1995-11-06
申请人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , KOJIMA, Atsuyuki , ANTOKU, Fujio , YOSHIGI, Mayumi , TANNO, Norihiko , NISHIHARA, Toshio , TOYODA, Tomohiro , OHNO, Yukihiro
发明人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
IPC分类号： C07D209/46
CPC分类号： C07D401/06 , C07D209/48 , C07D401/14 , C07D403/12 , C07D413/14 , C07D417/12 , C07D493/08
摘要： A lactam derivative represented by general formula (A) or an acid-addition salt thereof, having excellent characteristics as a psychotropic drug, and being useful as a remedy for schizophrenia, senile psychosis, manic-depressive psychosis, neurosis, and so forth, wherein R , R , R and R represent each hydrogen or lower alkyl, provided a pair of R and R , R and R , R and R , or R and R may form a hydrocarbon ring which may be bridged with lower alkylene or oxygen, and the lower alkylene and the hydrocarbon ring may be substituted by at least one alkyl group; n represents 0 or 1; A represents lower alkylene, lower alkenylene or a hydrocarbon ring which may be bridged with lower alkylene (which may be substituted by at least one alkyl or hydroxy group) or oxygen, and the lower alkylene, the lower alkenylene and the hydrocarbon ring may be each substituted by at least one alkyl or hydroxy group; p and q represent each 0, 1 or 2; and G represents N or CH and Ar represents a heteroaryl or aromatic hydrocarbon group, or alternatively G represents CH and Ar represents phenoxy, provided the heteroaryl group, the aromatic hydrocarbon group and the phenoxy group may be each substituted by at least one lower alkyl, lower alkoxy or halogeno.
摘要翻译：由通式（A）表示的内酰胺衍生物或其酸加成盐作为精神药物具有优异的特性，可用作精神分裂症，老年性精神病，躁狂抑郁性精神病，神经症等的补救剂，其中 R 1，R 2，R 3和R 4各自代表氢或低级烷基，只要一对R 1和R 2，R 3和R 4， R 1和R 3，或R 2和R 4可以形成可以与低级亚烷基或氧桥连的烃环，并且低级亚烷基和烃环可以被至少一个烷基; n表示0或1; A代表低级亚烷基，低级亚烯基或可与低级亚烷基（可被至少一个烷基或羟基取代）或氧键连接的烃环，低级亚烷基，低级亚烯基和烃环可以各自独立地被至少一个烷基或羟基取代; p和q分别代表0,1或2; 并且G表示N或CH，Ar表示杂芳基或芳族烃基，或者G表示CH，Ar表示苯氧基，条件是杂芳基，芳香族烃基和苯氧基可以各自被至少一个低级烷基，低级烷氧基或卤代。

40. 发明申请

WO1995017881A1 CONTROLLED-RELEASE PHARMACEUTICAL PREPARATION 审中-公开
标题翻译：控制释放药物制备
公开(公告)号：WO1995017881A1
公开(公告)日：1995-07-06
申请号：PCT/JP1994002208
申请日：1994-12-26
申请人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , DOW CORNING ASIA LTD.
发明人： SUMITOMO PHARMACEUTICALS COMPANY, LIMITED , DOW CORNING ASIA LTD. , FUJIOKA, Keiji , SANO, Akihiko , KAJIHARA, Masako , HIRASAWA, Takeshi , URABE, Yosuke , SUGAWARA, Shuichi
IPC分类号： A61K09/00
CPC分类号： A61K9/0092
摘要： A pharmaceutical preparation for releasing a water-soluble drug in vivo at a constant rate for long for achieving a prolonged drug effect. The preparation is in the form of a column composed of an inner layer prepared from a nondisintegratable biocompatible material containing a homogeneously dispersed water-soluble drug and an outer layer prepared from a water-impermeable biocompatible material which envelops the inner layer and can control the swelling of the inner layer. The ratio of the length of the section of the inner layer and the length in the axial direction of the preparation is 1 or above, and the inner layer is opened at one or both of its ends so as to come into direct contact with the outer atmosphere.
摘要翻译：用于长时间以恒定速率释放水溶性药物的药物制剂用于实现长时间的药物作用。该制剂是由由含有均匀分散的水溶性药物的不可分解生物相容性材料制备的内层和由不透水的生物相容性材料制成的外层组成的柱的形式，其包封内层并可控制肿胀的内层。内层的截面长度与制剂的轴向长度的比例为1以上，内层在其一端或两端开口以与外层直接接触大气层。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式